For investors evaluating emerging medical technology companies, the competitive advantages behind a product can be as important as financial results. That was the focus of a recent Medsider interview with Dr. Sudhir Srivastava, founder, chairman and CEO of SS Innovations International (NASDAQ: SSII), a developer of innovative surgical robotic technologies. Dr. Srivastava discussed the company’s strategy to broaden access to robotic surgery through lower-cost technology, physician training and remote surgical capabilities.
Affordability and accessibility remain the company’s core priorities as it expands its surgical robotics platform globally. Artificial intelligence, automation, and new robotic platforms are central to the company’s long-term product roadmap. Telesurgery and teleproctoring are becoming important differentiators, allowing expert surgeons to support complex procedures remotely. The SSi Mantra system was designed to reduce the cost of robotic surgery while supporting multiple specialties, including cardiac surgery.
The company has installed more than 200 robotic systems and completed more than 11,700 robotic procedures, including over 170 telesurgeries. SS Innovations is pursuing FDA and European regulatory approvals while expanding into additional international markets. Rather than concentrating solely on competing with existing robotic surgery platforms, Dr. Srivastava described SS Innovations’ objective as expanding access to hospitals and patients that have historically been unable to adopt robotic surgery because of equipment costs and operating expenses.
For more information, please see the full terms of use and disclaimers on the InvestorBrandNetwork website at http://IBN.fm/Disclaimer. This article contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. These statements are subject to factors detailed in the company's SEC filings, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Undue reliance should not be placed on forward-looking statements, and the company undertakes no duty to update them unless required by law.
